Could a Copper-Binding drug shrink thickened heart muscle?

NCT ID NCT04706429

Completed Disease control Sponsor: Manchester University NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug trientine can reduce heart muscle thickening and improve exercise ability in people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. 154 adults with HCM took either trientine or a placebo for 12 months. The main goal was to see if the drug could shrink the heart muscle and improve heart function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Locations

Liverpool Heart and Chester Hospital NHS Foundation Trust

Liverpool, L14 3PE, United Kingdom
Manchester University NHS Foundation Trust

Manchester, M23 9LT, United Kingdom
NHS Grampian

Aberdeen, AB25 2ZN, United Kingdom
Northumbria Healthcare NHS Foundation Trust

North Shields, NE29 8NH, United Kingdom
Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 9DU, United Kingdom
Royal Brompton and Harefield NHS Foundation Trust

London, SW3 6NP, United Kingdom
University Hospitals of Leicester NHS Foundation Trust

Leicester, LE3 9QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.